KR102318875B1 - 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물 - Google Patents

헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물 Download PDF

Info

Publication number
KR102318875B1
KR102318875B1 KR1020200033737A KR20200033737A KR102318875B1 KR 102318875 B1 KR102318875 B1 KR 102318875B1 KR 1020200033737 A KR1020200033737 A KR 1020200033737A KR 20200033737 A KR20200033737 A KR 20200033737A KR 102318875 B1 KR102318875 B1 KR 102318875B1
Authority
KR
South Korea
Prior art keywords
cancer
pharmaceutically acceptable
acceptable salt
phosphorus compound
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020200033737A
Other languages
English (en)
Korean (ko)
Other versions
KR20200111644A (ko
Inventor
이윤호
강주희
강세인
김환
김승수
석지윤
고이경
김다은
한아름
류민석
황동근
고은화
최환근
이선화
손정범
김남두
Original Assignee
보로노이 주식회사
보로노이바이오 주식회사
주식회사 비투에스바이오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 보로노이 주식회사, 보로노이바이오 주식회사, 주식회사 비투에스바이오 filed Critical 보로노이 주식회사
Publication of KR20200111644A publication Critical patent/KR20200111644A/ko
Priority to KR1020210141386A priority Critical patent/KR102564533B1/ko
Application granted granted Critical
Publication of KR102318875B1 publication Critical patent/KR102318875B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020200033737A 2019-03-19 2020-03-19 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물 Active KR102318875B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020210141386A KR102564533B1 (ko) 2019-03-19 2021-10-21 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR1020190031269 2019-03-19
KR20190031269 2019-03-19
KR20190134472 2019-10-28
KR1020190134472 2019-10-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020210141386A Division KR102564533B1 (ko) 2019-03-19 2021-10-21 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물

Publications (2)

Publication Number Publication Date
KR20200111644A KR20200111644A (ko) 2020-09-29
KR102318875B1 true KR102318875B1 (ko) 2021-11-01

Family

ID=72521153

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020200033737A Active KR102318875B1 (ko) 2019-03-19 2020-03-19 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물
KR1020210141386A Active KR102564533B1 (ko) 2019-03-19 2021-10-21 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020210141386A Active KR102564533B1 (ko) 2019-03-19 2021-10-21 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물

Country Status (22)

Country Link
US (2) US12152021B2 (https=)
EP (2) EP4631507A3 (https=)
JP (2) JP7109013B2 (https=)
KR (2) KR102318875B1 (https=)
CN (3) CN114605400B (https=)
AU (2) AU2020240382B2 (https=)
BR (1) BR112021018704B1 (https=)
CA (1) CA3134261A1 (https=)
DK (1) DK3943491T3 (https=)
ES (1) ES3036467T3 (https=)
FI (1) FI3943491T3 (https=)
HU (1) HUE073283T2 (https=)
IL (2) IL299831B2 (https=)
MA (1) MA55380A (https=)
MX (1) MX2021011160A (https=)
NZ (2) NZ790920A (https=)
PL (1) PL3943491T3 (https=)
PT (1) PT3943491T (https=)
SG (1) SG11202110376XA (https=)
SI (1) SI3943491T1 (https=)
WO (1) WO2020190119A1 (https=)
ZA (1) ZA202107889B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
AU2020240382B2 (en) 2019-03-19 2022-08-25 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
TW202227425A (zh) * 2020-09-18 2022-07-16 南韓商沃若諾伊生物公司 雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物
KR20220085735A (ko) * 2020-12-14 2022-06-22 보로노이바이오 주식회사 아이소옥사졸리딘 유도체 화합물 및 이의 용도
EP4323356A1 (en) 2021-04-13 2024-02-21 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
EP4335847A1 (en) * 2021-05-07 2024-03-13 Voronoi Inc. Heteroaryl derivative, method for preparing same, and pharmaceutical composition comprising same as active ingredient
CN115667251A (zh) * 2021-05-17 2023-01-31 株式会社沃若诺伊生物 杂芳基衍生物化合物、及其用途
KR102563834B1 (ko) * 2021-06-28 2023-08-04 순천대학교 산학협력단 세포자멸사를 유도하는 신규한 화합물 및 이를 포함하는 항암용 조성물
CN117430600A (zh) * 2022-07-20 2024-01-23 上海和誉生物医药科技有限公司 一种选择性egfr抑制剂及其制备方法和在药学上的应用
KR20250043424A (ko) 2022-08-05 2025-03-28 미쓰비시 마테리알 가부시키가이샤 절삭 공구
CN120035590A (zh) * 2022-11-03 2025-05-23 株式会社沃若诺伊 Egfr抑制剂的延胡索酸盐、酒石酸盐、苹果酸盐和柠檬酸盐
EP4611902A1 (en) 2022-11-03 2025-09-10 Oric Pharmaceuticals, Inc. Malonate and glycolate salts of an egfr inhibitor
AU2023381004A1 (en) * 2022-11-15 2025-04-10 Voronoi, Inc. Heteroaryl derivative compound, and uses thereof
MX2025012495A (es) * 2023-05-05 2026-02-03 Oric Pharmaceuticals Inc Inhibidor del receptor del factor de crecimiento epidérmico (egfr) para tratamiento de cánceres con mutaciones atípicas del factor de crecimiento epidérmico
WO2026080372A1 (en) 2024-10-07 2026-04-16 Oric Pharmaceuticals, Inc. Treatment of cancers comprising egfr extracellular and transmembrane mutations

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
WO2005026129A1 (en) 2003-09-15 2005-03-24 Gpc Biotech Ag Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
WO2006125616A2 (en) 2005-05-25 2006-11-30 Ingenium Pharmaceuticals Ag Pyrimidine-based cdk inhibitors for treating pain
TW200804364A (en) 2006-02-22 2008-01-16 Boehringer Ingelheim Int New compounds
EA200901133A1 (ru) 2007-03-20 2010-04-30 Смитклайн Бичем Корпорейшн Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
JP2011102241A (ja) 2008-03-04 2011-05-26 Dainippon Sumitomo Pharma Co Ltd 新規１−アミノカルボニルピペリジン誘導体
KR101906146B1 (ko) 2009-08-17 2018-10-10 메모리얼 슬로안-케터링 캔서 센터 열 충격 단백질 결합 화합물, 조성물, 및 이의 제조 방법 및 사용 방법
KR101401664B1 (ko) 2011-11-15 2014-06-11 중앙대학교 산학협력단 신경줄기세포 분화조절제용 신규 피리미딘-2,4-디아민 유도체 및 이의 의학적 용도
US8871778B2 (en) 2012-01-20 2014-10-28 Genosco Substituted pyrimidine compounds and their use as SYK inhibitors
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
WO2014055928A2 (en) 2012-10-04 2014-04-10 University Of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
EP2769722A1 (en) 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Compounds for use in inhibiting HIV capsid assembly
EP2970240B1 (en) 2013-03-14 2018-01-10 Novartis AG 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
EP3037424B1 (en) 2013-08-22 2017-11-08 Taiho Pharmaceutical Co., Ltd. Novel quinoline-substituted compound
BR112016008632A8 (pt) 2013-10-21 2020-03-17 Merck Patent Gmbh compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica
KR20150047855A (ko) 2013-10-25 2015-05-06 한미약품 주식회사 단백질 카이네이즈 억제 효과를 갖는 2-사이아노-아크릴아마이드 유도체
EP3143015B1 (en) 2014-05-13 2019-02-20 ARIAD Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CN110526912B (zh) 2014-06-19 2023-02-14 武田药品工业株式会社 用于激酶抑制的杂芳基化合物
CN117069700B (zh) * 2014-10-11 2026-01-30 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备和应用
EP3929190B1 (en) * 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
EP3206691B1 (en) 2014-10-14 2018-09-19 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
CN113563332B (zh) 2014-12-23 2024-12-17 达纳－法伯癌症研究所公司 作为egfr抑制剂的新的嘧啶和治疗病症的方法
JP6970081B2 (ja) 2015-07-16 2021-11-24 正大天晴▲藥▼▲業▼集▲団▼股▲フン▼有限公司 アニリンピリミジン誘導体及びその使用
CN106478607B (zh) 2015-08-28 2019-05-24 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
US10377747B2 (en) 2015-08-31 2019-08-13 Wuxi Shuangliang Biotechnology Co., Ltd. 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof
CN108602809B (zh) 2015-12-04 2022-09-30 戴纳立制药公司 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂
EP3399968B8 (en) 2016-01-07 2021-12-01 Xuanzhu Biopharmaceutical Co., Ltd. Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
WO2017156527A1 (en) 2016-03-11 2017-09-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase and janus kinase inhibitors for prevention of graft versus host disease
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
US11352352B2 (en) 2017-06-13 2022-06-07 Beijing Adamadle Biotechnology Limited Liability Company Aminopyrimidine compound, preparation method therefor and use thereof
CN111093645A (zh) * 2017-07-05 2020-05-01 Cs制药技术有限公司 Egfr酪氨酸激酶的临床上重要的突变体的选择性抑制剂
US11339157B1 (en) 2017-10-24 2022-05-24 Bayer Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
TWI798334B (zh) 2018-01-31 2023-04-11 大陸商迪哲（江蘇）醫藥股份有限公司 Ｅｒｂｂ／ｂｔｋ抑制劑
CN108191774B (zh) 2018-01-31 2022-05-24 中国药科大学 一类杂环化合物、其制备方法和用途
WO2019177374A1 (ko) 2018-03-13 2019-09-19 포로노이바이오 주식회사 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물
KR102782739B1 (ko) 2018-03-13 2025-03-20 보로노이 주식회사 2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
US12084431B2 (en) 2018-05-14 2024-09-10 Takeda Pharmaceutical Company Limited Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
CN109280048A (zh) 2018-11-16 2019-01-29 江西科技师范大学 一种含取代苯基丙烯酰胺结构的嘧啶类化合物及其应用
CN109608394A (zh) 2018-12-03 2019-04-12 湖南大学 氮杂芳胺类化合物的合成方法和氮杂芳胺类化合物
AU2020240382B2 (en) * 2019-03-19 2022-08-25 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component

Also Published As

Publication number Publication date
IL286471B2 (en) 2023-08-01
AU2020240382B2 (en) 2022-08-25
US11466000B2 (en) 2022-10-11
MA55380A (fr) 2022-01-26
NZ781366A (en) 2022-08-26
CN113993866A (zh) 2022-01-28
JP7394298B2 (ja) 2023-12-08
EP4631507A2 (en) 2025-10-15
MX2021011160A (es) 2022-02-10
IL299831B2 (en) 2025-12-01
ZA202107889B (en) 2024-02-28
AU2022211789B2 (en) 2024-06-27
EP3943491A1 (en) 2022-01-26
SI3943491T1 (sl) 2025-08-29
KR20210130123A (ko) 2021-10-29
US20220073505A1 (en) 2022-03-10
JP2022125283A (ja) 2022-08-26
PT3943491T (pt) 2025-07-28
EP3943491A4 (en) 2022-11-23
DK3943491T3 (da) 2025-07-14
AU2022211789A1 (en) 2022-08-25
KR20200111644A (ko) 2020-09-29
AU2020240382A1 (en) 2021-11-11
EP3943491B1 (en) 2025-06-18
BR112021018704A2 (https=) 2021-11-23
BR112021018704B1 (pt) 2023-01-10
ES3036467T3 (en) 2025-09-19
IL299831A (en) 2023-03-01
JP2022522250A (ja) 2022-04-14
FI3943491T3 (fi) 2025-07-31
US20220162203A1 (en) 2022-05-26
WO2020190119A1 (ko) 2020-09-24
CN114605400A (zh) 2022-06-10
CN115838369A (zh) 2023-03-24
IL286471B1 (en) 2023-04-01
CN113993866B (zh) 2022-10-28
IL286471A (en) 2021-12-01
PL3943491T3 (pl) 2025-11-17
US12152021B2 (en) 2024-11-26
JP7109013B2 (ja) 2022-07-29
EP4631507A3 (en) 2025-12-24
IL299831B1 (en) 2025-08-01
CN114605400B (zh) 2024-09-10
KR102564533B1 (ko) 2023-08-08
CA3134261A1 (en) 2020-09-24
NZ790920A (en) 2026-02-27
HUE073283T2 (hu) 2026-01-28
SG11202110376XA (en) 2021-10-28

Similar Documents

Publication Publication Date Title
KR102318875B1 (ko) 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물
AU2017245469A1 (en) Aminopyrimidine derivatives for use as modulators of kinase activity
JP7790746B2 (ja) ヘテロアリール誘導体、そのヘテロアリール誘導体の調製方法、及びそのヘテロアリール誘導体を活性成分として含む医薬組成物
CN113853375B (zh) 含n杂芳基衍生物及包含其作为活性成分的用于预防或治疗癌症的药物组合物
US20240150337A1 (en) Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
KR20230163335A (ko) 헤테로아릴 유도체 화합물 및 이의 용도
TWI867047B (zh) 雜芳基衍生物、其製備方法、及含彼作為活性成份之藥學組成物
CN115109036A (zh) 一种喹唑啉类化合物、组合物及其应用
HK40074494A (en) Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
HK40066923A (zh) 杂芳基衍生物、其制备方法、及含其作为有效成分的药物组合物
HK40066923B (en) Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
HK40062266B (en) Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
HK40090980A (zh) 杂芳基衍生物、其制备方法、及含其作为有效成分的药物组合物
HK40074494B (zh) 杂芳基衍生物、其制备方法、及含其作为有效成分的药物组合物
HK40062266A (en) Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
TWI820414B (zh) 喹唑啉類化合物、製備方法及其應用
EA041448B1 (ru) Гетероарильное производное и содержащая его фармацевтическая композиция

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20200319

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210705

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 20200319

Comment text: Patent Application

PA0302 Request for accelerated examination

Patent event date: 20210705

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

Patent event date: 20200319

Patent event code: PA03021R01I

Comment text: Patent Application

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210917

A107 Divisional application of patent
PA0107 Divisional application

Comment text: Divisional Application of Patent

Patent event date: 20211021

Patent event code: PA01071R01D

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20211022

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20211025

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240919

Start annual number: 4

End annual number: 4